目的：研究生物人工角膜联合更昔洛韦治疗病毒性角膜炎的效果及对血清炎症因子的影响。

方法：选取病毒性角膜炎患者54例54眼，随机分为观察组和对照组，在生物人工角膜移植手术基础上，观察组予以更昔洛韦治疗，对照组予以阿昔洛韦治疗。观察两组视力、角膜透明度、血清炎性因子以及细胞因子的变化情况。

结果：观察组和研究组的脱盲率分别为93%、89%(P=0.642)； 两组术后1wk，6mo视力与术前相比均明显改善(P<0.05)。术后7d，两组IL-6、TNF-α、INF-γ、SOD、NO、MDA水平均较治疗前明显改善，且观察组指标改善优于对照组(P<0.05)。两组不良反应无显著差异(P=0.556)。

结论：生物人工角膜联合更昔洛韦治疗病毒性角膜炎疗效良好，提高视力，改善炎症情况，降低MDA水平。

METHODS: In this study, 54 patients with 54 eyes were selected as the research object and divided into the observation group and the control group according to the random number table method. All patients were treated with bioartificial corneal transplantation. The patients in the observation group were treated with Ganciclovir eye drops, and the control group was treated with Aciclovir eye drops. The changes of LogMAR visual acuity, corneal transparency, serum inflammatory factors and cytokines were analyzed.

RESULTS: The rates of getting rid of blindness in the observation group and the study group were 93% and 89% respectively(P=0.642). The LogMAR visual acuity of two groups were significantly improved in 1wk and 6mo after operation compared with that before operation(P<0.05). At 7d after operation, the levels of IL-6, TNF-α, INF- γ, SOD, NO and MDA in the two groups were significantly improved, and the improvement of the indexes in the observation group was better than that of the control group(P<0.05). The rate of adverse reaction rate between two groups showed no significant difference(P=0.556).

CONCLUSION: Biological keratoconus combined with Ganciclovir has a good effect on viral keratitis, which can improve vision, inflammation and reduce the level of MDA.